Posted by Michael Wonder on 11 Oct 2017
Xeljanz receives positive reimbursement decision in England
11 October 2017 - The UK’s HTA body NICE has provided final guidance recommending Xeljanz (tofacitinib citrate) as a treatment option for adults with severe active rheumatoid arthritis.
The decision means Pfizer’s JAK inhibitor will be reimbursed on the National Health Service in England.
The recommendation applies to adults whose disease has responded inadequately to intensive therapy with conventional or other disease-modifying anti-rheumatic drugs.
